Literature DB >> 34388714

Treatment strategies for giant pituitary adenomas in the era of endoscopic transsphenoidal surgery: a multicenter series.

Alexander Micko1,2, Matthew S Agam1, Andrew Brunswick1, Ben A Strickland1, Martin J Rutkowski1, John D Carmichael3, Mark S Shiroishi4, Gabriel Zada1, Engelbert Knosp2, Stefan Wolfsberger2.   

Abstract

OBJECTIVE: Given the anatomical complexity and frequently invasive growth of giant pituitary adenomas (GPAs), individually tailored approaches are required. The aim of this study was to assess the treatment strategies and outcomes in a large multicenter series of GPAs in the era of endoscopic transsphenoidal surgery (ETS).
METHODS: This was a retrospective case-control series of 64 patients with GPAs treated at two tertiary care centers by surgeons with experience in ETS. GPAs were defined by a maximum diameter of ≥ 4 cm and a volume of ≥ 10 cm3 on preoperative isovoxel contrast-enhanced MRI.
RESULTS: The primary operation was ETS in all cases. Overall gross-total resection rates were 64% in round GPAs, 46% in dumbbell-shaped GPAs, and 8% in multilobular GPAs (p < 0.001). Postoperative outcomes were further stratified into two groups based on extent of resection: group A (gross-total resection or partial resection with intracavernous remnant; 21/64, 33%) and group B (partial resection with intracranial remnant; 43/64, 67%). Growth patterns of GPAs were mostly round (11/14, 79%) in group A and multilobular (33/37, 89%) in group B. In group A, no patients required a second operation, and 2/21 (9%) were treated with adjuvant radiosurgery. In group B, early transcranial reoperation was required in 6/43 (14%) cases due to hemorrhagic transformation of remnants. For the remaining group B patients with remnants, 5/43 (12%) underwent transcranial surgery and 12/43 (28%) underwent delayed second ETS. There were no deaths in this series. Severe complications included stroke (6%), meningitis (6%), hydrocephalus requiring shunting (6%), and loss or distinct worsening of vision (3%). At follow-up (mean 3 years, range 0.5-16 years), stable disease was achieved in 91% of cases.
CONCLUSIONS: ETS as a primary treatment modality to relieve mass effect in GPAs and extent of resection are dependent on GPA morphology. The pattern of residual pituitary adenoma guides further treatment strategies, including early transcranial reoperation, delayed endoscopic transsphenoidal/transcranial reoperation, and adjuvant radiosurgery.

Entities:  

Keywords:  endoscopic; giant pituitary adenoma; invasive; outcome; pituitary surgery

Mesh:

Year:  2021        PMID: 34388714     DOI: 10.3171/2021.1.JNS203982

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  4 in total

1.  Classifying Pituitary Adenoma Invasiveness Based on Radiological, Surgical and Histological Features: A Retrospective Assessment of 903 Cases.

Authors:  Liang Lu; Xueyan Wan; Yu Xu; Juan Chen; Kai Shu; Ting Lei
Journal:  J Clin Med       Date:  2022-04-27       Impact factor: 4.964

2.  Surgical Experience of Transcranial Approaches to Large-to-Giant Pituitary Adenomas in Knosp Grade 4.

Authors:  Xiudong Guan; Yangyang Wang; Chengkai Zhang; Shunchang Ma; Wenjianlong Zhou; Guijun Jia; Wang Jia
Journal:  Front Endocrinol (Lausanne)       Date:  2022-05-12       Impact factor: 6.055

3.  Analysis of neuroendoscopy for the treatment of macroadenomas and giant pituitary adenomas.

Authors:  Junyong Wu; Binbin Zhang; Dongqi Shao; Shuxin Ji; Yu Li; Shan Xie; Zhiquan Jiang
Journal:  Front Surg       Date:  2022-08-11

4.  Outcome of giant pituitary tumors requiring surgery.

Authors:  Stephan Gaillard; Sosthène Adeniran; Chiara Villa; Anne Jouinot; Marie-Laure Raffin-Sanson; Loic Feuvret; Pierre Verrelle; Fidéline Bonnet; Anthony Dohan; Jérôme Bertherat; Guillaume Assié; Bertrand Baussart
Journal:  Front Endocrinol (Lausanne)       Date:  2022-08-29       Impact factor: 6.055

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.